IAS (International AIDS Society) Conference

The Latest

Cross-Resistance Between Integrase Inhibitors

HIV integrase inhibitors represent a new class of antiretroviral drugs that target a crucial post-transcriptional event in the life cycle of HIV. There is considerable excitement about the potential of this new class of antiretroviral agents to revol...

By Graeme Moyle, M.D., M.B., B.S., Dip. G.U.M.

Faster Viral Decay With Raltegravir

The lead agent in the integrase inhibitor drug class, raltegravir (RAL, MK-0518) has demonstrated potent antiretroviral activity in phase 2 and 3 clinical trials conducted in both treatment-naive1 and treatment-experienced individuals2 when combined ...

By Graeme Moyle, M.D., M.B., B.S., Dip. G.U.M.